Evidence map›Paper›PMID 34166757›Full record

ArticleAnnals of oncology : official journal of the European Society for Medical Oncology2021

Reply to: 'Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.' by D. Fabrizio et al.

D J McGrail, P G Pilié, N U Rashid, L Voorwerk, M Slagter, M Kok, E Jonasch, M Khasraw, A B Heimberger, N T Ueno and 3 more

Abstract readLetterComment
PubMed Publisher
In one paragraph

Article in Annals of oncology : official journal of the European Society for Medical Oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Validation of cancer-type-dependent benefit from immune checkpoint blockade in TMB-H tumors identified by the FoundationOne CDx assay.Annals of oncology : official journal of the European Society for Medical Oncology · 2022
    Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 2 countries.

D J McGrailDepartment of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: djmcgrail@mdanderson.org.
P G PiliéDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
N U RashidLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, USA; Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, USA.
L VoorwerkDivision of Tumor Biology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
M SlagterDivision of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Oncode Institute, Utrecht, the Netherlands.
M KokDivision of Tumor Biology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
E JonaschDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
M KhasrawThe Preston Robert Tisch Brain Tumor Center, Duke University, Durham, USA.
A B HeimbergerDepartment of Neurological Surgery, Northwestern University, Chicago, USA; Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago.
N T UenoDepartment of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
R FerrarottoDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
J T ChangDepartment of Integrative Biology and Pharmacology, The University of Texas Health Sciences Center at Houston, Houston, USA; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, USA.
S-Y LinDepartment of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: sylin@mdanderson.org.
The University of Texas MD Anderson Cancer Center · USOncode Institute · NLDuke University · USNorthwestern University · USThe Netherlands Cancer Institute · NLUniversity of North Carolina at Chapel Hill · US

Funding

Determining the Immunological Consequences of DNA Replication Stress Response Defects in Renal Cells Carcinoma to Improve Immunotherapy OutcomesK99CA240689 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MCGRAIL, DANIEL JAMES · 2019 to 2020
$207k
NCI NIH HHS K99 CA240689
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antibodies, Monoclonal, HumanizedNeoplasmsHumansPrevalenceAntibodies, Monoclonal, Humanizedpembrolizumab

Identifiers

PMID34166757
OpenAlexW3174833004

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.